SUPERNOVA is a Phase III trial looking at the safety and efficacy of sipavibart, a long-acting antibody to prevent COVID-19 infection in individuals who are immunocompromised. On May 16th, 2024, AstraZeneca published a press release to announce the trial has met its primary endpoints.
While little detail has been released to the public, we know the trial has met its two primary endpoints:
- Reduced the relative risk of symptomatic COVID-19 caused by any SARS-CoV-2 variant.
- Reduced the relative risk of infections caused by SARS-CoV-2 variants not containing the F456L mutation.
This study was occurring during a shifting landscape of different SARS-CoV-2 variants.
The SUPERNOVA trial studied sipavibart in “immunocompromised patients [including] those with blood cancer, organ transplant recipients, patients with end-stage renal disease requiring dialysis, patients receiving B-cell depleting therapy within the past year, and those taking immunosuppressive medications.”
The results will be shared with the FDA, and hopefully, vulnerable CLL / SLL patients who don’t respond well to COVID-19 vaccines will soon have a second option for pre-exposure prophylaxis (PrEP). Pemgarda is already authorized for PrEP.
For more details, please see the AstraZeneca press release: SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population
CLL Society will be meeting with the team who are responsible for sipavibart and will share what we learn.
